|
Horne, Benjamin D; Lenzini, Petra A; Wadelius, Mia et al. (2012) Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost 107:232-40
|
|
Lenzini, P; Wadelius, M; Kimmel, S et al. (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87:572-8
|
|
Voora, D; Koboldt, D C; King, C R et al. (2010) A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 87:445-51
|
|
King, Cristi R; Deych, Elena; Milligan, Paul et al. (2010) Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 104:750-4
|
|
Ferder, N S; Eby, C S; Deych, E et al. (2010) Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 8:95-100
|
|
Limdi, Nita A; Wadelius, Mia; Cavallari, Larisa et al. (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115:3827-34
|
|
International Warfarin Pharmacogenetics Consortium; Klein, T E; Altman, R B et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-64
|
|
Linder, Mark W; Bon Homme, Marjorie; Reynolds, Kristen K et al. (2009) Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin Chem 55:1861-8
|
|
Gage, B F; Eby, C; Johnson, J A et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326-31
|
|
King, Cristi R; Porche-Sorbet, Rhonda M; Gage, Brian F et al. (2008) Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 129:876-83
|
Showing the most recent 10 out of 20 publications
